Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis

Author(s): Francesco Piazza, Sabrina Manni, Anna Colpo, Laura Quotti Tubi, Carmela Gurrieri, Gianpietro Semenzato

Journal Name: Current Signal Transduction Therapy

Volume 6 , Issue 1 , 2011

Become EABM
Become Reviewer
Call for Editor


Cellular protein kinases (PKs) have critical roles in regulating the hallmarks of cancer (autonomous cell growth, resistance to antigrowth signals, unlimited replication, neoangiogenesis, tissue invasion and metastasis). Consequently, a strong rationale drives those therapeutic strategies aimed at targeting PKs to achieve tumour regression. Haematological malignancies have been at the forefront in this field of investigation, as major successes with the use of PKs inhibitors have been obtained in the therapy of some types of leukaemia. We will herein review the established and potential roles of three serine-threonine PKs, CK1, CK2 and GSK3 in normal and malignant haematopoiesis. These PKs regulate a multitude of cellular processes, are either over-expressed or hyper-activated in leukaemia, multiple myeloma and lymphoma cells and are essential for cell survival and resistance to apoptosis through their interaction with critical signal transduction pathways. However, the knowledge of their function in normal and malignant haematopoiesis is only at the beginning. Consequently, a more precise description of these “druggable” kinases specifically in blood cells, which is a prerequisite to rationally develop targeted therapeutic approaches, will necessarily be achieved through the use of molecular, genetic and animal experimental models.

Keywords: Apoptosis, haematopoiesis, kinase inhibitors, leukaemia, myeloma, protein kinases, stem cell, targeted therapy, acute myeloid leukaemias (AML), chronic myeloid leukaemia (CML), non-Hodgkin's lymphomas, Hodgkin's lymphoma, multiple myeloma, tyrosine kinases, serine-threonine kinases, receptor TKs (RTKs), cytoplasmic TKs (CTKs), internal tandem duplication (ITD) of t, chronic myelo-monocytic leukaemia (CMML), V617F, STAT5, myeloproliferative disorders, GSK3, CK1, CK2, Y216, adenomatous polyposis coli (APC), axin, axin2, haema-topoietic stem cell (HSC), Hedgehog (Hh) Pathway, PTEN, Phosphatidylinositol 3,4,5-triphosphate (PIP3), DLBC, CARMA1, BCL9, MALT1, PI3K/AKT, p-PDK1, pFKHR, p-BAD, Bcl-2, Bcl-xL, Mcl-1

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [88 - 98]
Pages: 11
DOI: 10.2174/157436211794109370

Article Metrics

PDF: 55